Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study

Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study

BackgroundImmune checkpoint inhibitors (ICIs) have become the standard second-line treatment for advanced non-small cell lung cancer (NSCLC). Recent findings indicating an intertwined regulation of vascular endothelial growth factor (VEGF) signaling and immunosuppression in the tumor microenvironmen...

Full description

Bibliographic Details
Main Authors: Bo Yang, Yuzhi Li, Jie Deng, Hui Yang, Xiang Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
recombinant human endostatin
anti-angiogenesis
immune checkpoint inhibitors
second-line
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1210267/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1210267/full

Similar Items